IKS Health announced a robust 21.5% year-over-year increase in revenue for Q2 FY26, reaching INR 7,811 million. This growth is attributed to the increasing adoption of its AI-driven platform and strategic client relationships. The company’s EBITDA also saw a significant rise of 43.2% YoY. IKS Health is focused on continuing its growth trajectory through strategic investments and technological advancements.
Financial Performance Highlights
IKS Health reported strong financial results for Q2 FY26, demonstrating significant growth and improved profitability:
- Revenue: Increased by 21.5% year-over-year to INR 7,811 million.
- EBITDA: Rose by 43.2% year-over-year to INR 2,718 million.
- PAT: Increased by 59.9% year-over-year to INR 1,807 million.
- Adjusted PAT: Reached INR 1,981 million, a 53.6% year-over-year increase.
The company’s EBITDA margin stood at 34.8% and PAT margin at 23.1% for the quarter.
Key Growth Drivers
The impressive Q2 FY26 performance was driven by several strategic factors:
- Increased adoption of the Agentic AI platform, enhancing efficiency and outcomes.
- Strong relationships with enterprise-level clients (450+), contributing to repeat business.
- Strategic focus on outcome-oriented deals.
Strategic Initiatives
IKS Health is executing on five strategic pillars to drive future growth:
- Advancing its AI-native platform.
- Integrating and optimizing the AQuity acquisition.
- Establishing leadership in key features.
- Pursuing differentiated growth market strategies.
- Evolving towards an outcome-oriented company.
Cash Flow and Debt
The company continues to generate strong cash flow, supporting its growth aspirations. Net debt has decreased to INR 4,125 million as of September 30, 2025.
Source: BSE
